• Paolo Montuschi, Mario Malerba, Giuseppe Santini, and Marc Miravitlles.
• Department of Pharmacology, Faculty of Medicine, University Hospital Agostino Gemelli, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: pmontuschi@rm.unicatt.it.
• Drug Discov. Today. 2014 Dec 1;19(12):1928-35.

AbstractChronic obstructive pulmonary disease (COPD) is characterized by large phenotype variability, reflected by a highly variable response to pharmacological treatment. Nevertheless, current guidelines suggest that patients with COPD of similar severity should be treated in the same way. The phenotype-based pharmacotherapeutic approach proposes bronchodilators alone in the nonfrequent exacerbator phenotype and a combination of bronchodilators and inhaled corticosteroids in patients with asthma-COPD overlap syndrome (ACOS) and moderate-to-severe exacerbator phenotype. The clinical importance of phenotypes is changing the paradigm of COPD management from evidence-based to personalized medicine. However, the personalized pharmacological strategy of COPD has to be validated in future clinical studies.Copyright © 2014 Elsevier Ltd. All rights reserved.

14 keywords...

hide…